Advertisement

Topics

Latest "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" News Stories - Page: 5

20:19 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" found in our extensive news archives from over 250 global news sources.

More Information about Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 for you to read. Along with our medical data and news we also list Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Clinical Trials, which are updated daily. BioPortfolio also has a large database of Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018 Companies for you to search.

Showing "Oncolytics Biotech Announces Publication REOLYSIN Abstract AACR 2018" News Articles 101–125 of 36,000+

Tuesday 19th March 2019

2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets

2018 FINANCIAL RESULTS AND BUSINESS UPDATE: LANDMARK DEAL WITH ASTRAZENECA TO SUPPORT TRANSITION INTO A FULLY INTEGRATED ONCOLOGY-FOCUSED BIOTECH, STRONG CLINICAL PROGRESS IN LEAD ASSETS Cash, cash equivalents and financial assets[*] amounted to €202.7m (million euros) as of December 31, 2018 (€176.6m in 2017) Revenue and other income amounted to €94.0m (€36.2m in 2017) Operating expe...


MatriSys Bioscience announces successful FDA Pre-IND review and Phase 2 plans for MSB-01, a revolutionary human-microbiome based treatment for Atopic Dermatitis

SAN DIEGO, March 20, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a clinical stage biotechnology company developing rationally designed microbiome therapeutics to treat the top five skin diseases, today announced it has successfully completed a pre-IND (Investigational New Drug) review with the U.S. Food and Drug Administration (FDA). The FDA provided positive feedback regarding the plan...

Dynavax to Present on Inhaled TLR9 Agonist DV281 at the AACR Annual Meeting 2019

BERKELEY, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX), a fully-integrated biopharmaceutical company focused on discovering and developing novel vaccines and immuno-oncology therapeutics, today announced it will present safety and biomarker data for DV281, its inhaled TLR9 agonist, at the American Association for Cancer Research (AACR) Annual Meetin...


Kane Biotech Schedules Full Year 2018 Earnings Conference Call and Business Update

WINNIPEG, Manitoba, March 20, 2019 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE), (the “Corporation” or “Kane Biotech”), is pleased to announce today that it will host a conference call and webcast on Tuesday, March 26, 2019 at 4:00pm Eastern Time to discuss its financial results for the fourth quarter and full year 2018, in conjunction with the filing of its annual Year End Financ...

How about this blast from the past: Sage raises $90M in IPO. https://www.fiercebiotech.com/biotech/sage-soars-after-banking-90m-an-up-sized-ipo …

How about this blast from the past: Sage raises $90M in IPO. https://www.fiercebiotech.com/biotech/sage-soars-after-banking-90m-an-up-sized-ipo …

Techne Prime Thermal Cycler PCR 60 Well DNA Laboratory Serviced

£420.00End Date: Thursday Apr-18-2019 22:21:51 BSTBuy It Now for only: £420.00Buy It Now | Add to watch list Biotech365 : Techne Prime Thermal Cycler PCR 60 Well DNA Laboratory Serviced BioMarketplace You want to propose your products or a Biotech … Continue reading →

Abeona Therapeutics Inc.: Abeona Therapeutics gibt Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2018 bekannt

Auf Kurs für den Start der VITAL-Studie der Phase III zur Behandlung von RDEB Mitte 2019; EB-101 wird in eigener Produktionsanlage hergestellt werden Erhöhung der Produktionskapazitäten zur Unterst...

MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma (news with additional features)

DGAP-News: MorphoSys AG / Key word(s): Study 19.03.2019 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, and Shanghai, China, March 19, 2019   MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma   MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX...

The next issue of our free newsletter "Go West" drops tomorrow. Let @RebeccaDRobbins keep you up to date with the latest news on life sciences, #biotech, and #healthcare coming out of the West Coast. Sign up here: https://buff.ly/2HvWw6I 

The next issue of our free newsletter "Go West" drops tomorrow. Let @RebeccaDRobbins keep you up to date with the latest news on life sciences, #biotech, and #healthcare coming out of the West Coast. Sign up here: https://buff.ly/2HvWw6I 

Aurinia Pharmaceuticals, Inc. (AUPH) CEO Dr. Richard Glickman on Q4 2018 Results - Earnings Call Transcript

Maple Leaf Enters into a Consulting Agreement with DHC B.V.

CALGARY, Alberta, March 19, 2019 (GLOBE NEWSWIRE) — Maple Leaf Green World Inc. (“Maple Leaf” or the “Company”) (NEO: MGW, OTCQX: MGWFF) announces that the Company has entered into a consulting agreement (the “Agreement”) with a Dutch company DHC B.V. … Continue reading →

Valens GroWorks Announces $30 Million Bought Deal Financing & Acquisition of Strategic Assets

Kelowna, British Columbia--(Newsfile Corp. - March 19, 2019) - Valens GroWorks Corp. (CSE: VGW) (the "Company" or "Valens"), a multi-licensed provider of cannabis products and services focused on v...

What’s behind sky-high valuations of biopharma startups?

It was a banner year for biopharma, with records broken in deal values, number of exited unicorns and the biggest-ever biotech IPO. But where do these unicorn valuations come from?

Karuna brings in $68mm through its Series B round

Karuna Pharmaceuticals Inc. (muscarinic receptors for psychiatric and cognitive disorders) completed a $68mm Series B round; ...

Biohaven completes $125mm private placement through Royalty Pharma; could get $75mm more

Through a private placement, Biohaven Pharmaceutical Holding Co. Ltd. issued 2.5k preferred shares at $50.1k ($125mm) to Roya...

Provention Bio, Inc.'s (PRVB) CEO Ashleigh Palmer on Q4 2018 Results - Earnings Call Transcript

Provention Bio's (PRVB) CEO Ashleigh Palmer on Q4 2018 Results - Earnings Call Transcript

Concord Medical Announces New Appointments to Management Team

BEIJING, March 19, 2019 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading specialty hospital management solutions provider and an operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced three new appointments to the management team. Concord Medical's board of di...

What’s the current state of population health?

A survey conducted by Numerof & Associates in collaboration with Jefferson College of Population Health founding dean Dr. David Nash found progress toward implementing population health models appears to have slowed in 2018.

Aurinia Pharmaceuticals posts 4Q revenue of US$29 million

The pharma company reported a net loss of US$14.6 million or $0.17 per share in the fourth quarter ended December 31, 2018

CNL Healthcare Properties II Announces Agreement to Sell Medical Office Building, Estimated Net ...

Orlando, Fla., March 19, 2019 (GLOBE NEWSWIRE) Read more...

CNL Healthcare Properties Announces Net Asset Value Per Share of $10.01

Orlando, Fla., March 19, 2019 (GLOBE NEWSWIRE) Read more...

Amazon Choice Integrates with One Drop for Diabetes and Hypertension Management

One Drop, a provider of digital therapeutics solutions, today announced an integration partnership with Amazon’s exclusive health brand, Choice. The integration with One Drop’s app will provide Amazon’s Choice customers living with diabetes and hypertension with affordable, accessible, and comprehensive digital health management services. One Drop/Amazon Choice Integration Benefits Launched ...

‘Better decisions and shorter project timelines’: Optibrium taps InfoChem to up offering

Optibrium develops software for drug discovery and today announces a collaboration with InfoChem GmbH, a cheminformatics company, to provide users with a computer-aided synthesis design tool.

Human medicines European public assessment report (EPAR): Slenyto, melatonin, Sleep Initiation and Maintenance Disorders,Autistic Disorder, Date of authorisation: 20/09/2018, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Slenyto, melatonin, Sleep Initiation and Maintenance Disorders,Autistic Disorder, Date of authorisation: 20/09/2018, Revision: 1, Status: Authorised


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks